Exforge antitrust settlement caps Novartis’ year of legal disputes
Pharmaceutical Technology
JANUARY 6, 2023
The agreement outlined that Par would keep its generic equivalent off the market for as many as two years, delaying the generic launch till September 30, 2014. At the centre of the case was Gilenya’s ‘405 patent, which details methods for treating relapsing multiple sclerosis with a specific dosage of the drug.
Let's personalize your content